Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00388609 · ClinicalTrials.gov registry record · Phase 2
Multiple-dose Study to Evaluate the Efficacy, Safety and Pharmacokinetics of BMS-646256 in Obese Subjects
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 2
- Development phase
- 705
- Enrollment target
NCT00388609: Clinical Trial Phase 2 study, sponsored by Bristol-Myers Squibb.
NCT00388609 is a Phase 2 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 705 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (430% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00388609, a Phase 2 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 705 participants
- Enrollment target
Study Summary
The purpose of this study is to learn if BMS-646256 can cause weight loss in men and women who are: * overweight with high blood pressure or high cholesterol or * obese The safety of this treatment will also be studied
Interventions
- DRUG Placebo
- DRUG BMS-646256
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 705 participants |
| Start Date | 2006-11 |
| Est. Completion | 2009-04 |
| Phase | Phase 2 |
Why NCT00388609 stopped before completion
NCT00388609 is an interventional study that assigns participants to a tested intervention. The registered 705 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (430% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00388609 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00388609 about?
NCT00388609 is a clinical study titled "Multiple-dose Study to Evaluate the Efficacy, Safety and Pharmacokinetics of BMS-646256 in Obese Subjects". The purpose of this study is to learn if BMS-646256 can cause weight loss in men and women who are: * overweight with high blood pressure or high cholesterol or * obese The safety of this treatment will also be studied
What is the current status of trial NCT00388609?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 705 participants. The study started on 2006-11. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00388609?
The interventions under investigation include: Placebo (DRUG), BMS-646256 (DRUG).
Who is sponsoring clinical trial NCT00388609?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00388609's enrollment target sits among peer trials
705 45th of 2000 higher than 1,955 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06480383 · 705 participants · Phase 2
Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
- NCT07067463 · 705 participants · Phase 3
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
- NCT05796687 · 704 participants · NA
Evaluation of My Future Self, an New Teen Pregnancy Prevention Group Intervention for Youth in Non-traditional Settings
- NCT06350734 · 704 participants
Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia